Chen · Frontiers in immunology 2018 · systematic review and meta-analysis · n=71 studies (2,629 patients, 2,049 controls)

Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.

Cited 290 times in the scientific literature.

Level 3 - non-randomized controlled study

Systematic review and meta-analysis of observational case-control studies

PubMed 30283455 · doi:10.3389/fimmu.2018.02122 · record verified 2026-08-30

What was done

A systematic review and random-effects meta-analysis of studies indexed in PubMed and Web of Science was conducted to evaluate cerebrospinal fluid (CSF) inflammatory cytokine levels in patients with Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) compared to controls. The meta-analysis included 71 articles with a total of 2,629 patients and 2,049 controls.

What was found

The abstract reports statistically significant increases without numerical effect sizes, variance estimates, or p-values. Random-effects meta-analysis demonstrated that: - AD patients had significantly elevated CSF levels of TGF-β, MCP-1, and YKL-40 compared to controls. - PD patients had significantly heightened CSF levels of TGF-β1, IL-6, and IL-1β. - ALS patients had significantly increased CSF levels of G-CSF, IL-2, IL-15, IL-17, MCP-1, MIP-1α, TNF-α, and VEGF.

Why it matters

This meta-analysis synthesizes clinical evidence demonstrating that neurodegenerative disorders exhibit unique central nervous system inflammatory cytokine profiles, highlighting candidate CSF biomarkers for differential diagnosis and disease monitoring.

Limits

The abstract reports no numerical effect sizes, confidence intervals, or measures of between-study heterogeneity. As a synthesis of observational case-control data, it cannot establish causality or determine whether these cytokine aberrations precede neurodegeneration or represent secondary reactive inflammation. Potential confounders such as assay type, disease duration, severity, and patient medications are not described.

Cited by